Biology of Blood and Marrow Transplantation
Volume 13, Issue 12 , Pages 1469-1476 , December 2007

A Scheme for Defining Cause of Death and Its Application in the T Cell Depletion Trial

  • Edward Copelan

      Affiliations

    • Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH
    • Corresponding Author InformationCorrespondence and reprint requests: Edward A. Copelan, MD, Taussig Cancer Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, R35, Cleveland, OH 44195; Tel: 216-445-5647; Fax: 216-444-9464.
  • ,
  • James T. Casper

      Affiliations

    • Medical College of Wisconsin, Milwaukee, WI
  • ,
  • Shelly L. Carter

      Affiliations

    • The EMMES Corporation, Rockville, MD
  • ,
  • Jo-Anne H. van Burik

      Affiliations

    • University of Minnesota, Minneapolis, MN
  • ,
  • David Hurd

      Affiliations

    • Wake Forest University, Winston-Salem, NC
  • ,
  • Adam M. Mendizabal

      Affiliations

    • The EMMES Corporation, Rockville, MD
  • ,
  • John E. Wagner

      Affiliations

    • University of Minnesota, Minneapolis, MN
  • ,
  • Saul Yanovich

      Affiliations

    • Medical College of Virginia, Richmond, VA
  • ,
  • Nancy A. Kernan

      Affiliations

    • Memorial-Sloan Kettering Cancer Center, New York, NY

Received 10 August 2007 ,Accepted 27 August 2007.

References 

  1. Wagner JE, Thompson JS, Carter SL, et al. Impact of graft-versus-host disease prophylaxis on 3 year disease free survival in recipients of unrelated donor bone marrow transplantation: results of a multi-centre, randomized Phase II–III trial. Lancet. 2005;366:9487
  2. Weisdorf DJ, Hurd D, Carter S, et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant. 2003;9:512–518
  3. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562–1568
  4. Pavletic SZ, Carter SL, Kernan NA, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multi-center randomized trial in unrelated marrow donor transplantation. Blood. 2005;106:3308–3313
  5. Hofmeister CC, Marinier DE, Czerlanis C, et al. Clinical utility of autopsy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:26–30
  6. Van Burik JA, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis: an autopsy study of 355 patients. Medicine. 1998;77:246–254
  7. Cornetta K, Laughlin M, Carter S, et al. Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT) Study. Biol Blood Marrow Transplant. 2005;11:149–160
  8. Wall DA, Carter SL, Kernan NA, et al. Busulfan/melphalan/ATG followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the COBLT experience. Biol Blood Marrow Transplant. 2005;11:637–646
  9. Martin PL, Carter SL, Kernan NA, et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol Blood Marrow Transplant. 2005;12:184–194
  10. Cohen MH, French AL, Benning L, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med. 2002;113:91–98

 This work was supported by a contract from the National Heart, Lung and Blood Institute (N01-HB-47095 [J.E.W., J.H.V.], N01-HB-47097 [John S. Thompson, M.D., J.C., D.H., E.C.,S.Y.], N01-HB-47094 [S.L.C., A.M.M.] and N01-HB-47098 [N.A.K.]).

PII: S1083-8791(07)00436-3

doi: 10.1016/j.bbmt.2007.08.047

Biology of Blood and Marrow Transplantation
Volume 13, Issue 12 , Pages 1469-1476 , December 2007